Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: November 10, 1999
Event: Declaration of a Shareholder Rights Plan (Poison Pill) by the Board of Directors.
Key Financial Metrics
This filing is a current report regarding a corporate governance event and does not contain financial performance data such as revenue, profit, cash flow, or debt levels.
- Common Stock Outstanding (as of Oct 31, 1999): 1,522,169,258 shares
- Common Stock Reserved for Employee Plans: 76,592,025 shares
- Preferred Stock Reserved for Rights Exercise: 240,000 shares
- Dividend Distribution: One Right per outstanding share of Common Stock
- Record Date: December 1, 1999
Material Changes and Plan Mechanics
The Board declared a dividend of one Right for each share of Common Stock. These Rights are designed to deter hostile takeovers and will automatically attach to Common Stock certificates until a "Distribution Date."
- Trigger Event: The Rights become exercisable if an "Acquiring Person" acquires 10% or more of the outstanding Common Stock.
- Exercise Price: $200.00 per one ten-thousandth of a share of Series A Junior Participating Preferred Stock.
- Flip-In Provision: Upon a 10% acquisition, holders (excluding the Acquiring Person) may exercise Rights to receive Common Stock (or cash/property) with a value equal to two times the exercise price.
- Flip-Over Provision: If the Company is acquired in a merger or business combination following a 10% acquisition, holders may exercise Rights to receive stock of the acquiring company with a value equal to two times the exercise price.
- Voiding: Rights beneficially owned by an Acquiring Person become null and void upon triggering events.
- Expiration: November 10, 2009, unless redeemed or exchanged earlier.
Guidance, Outlook, and Management Commentary
Management Commentary: The filing states the Rights have anti-takeover effects and will cause substantial dilution to any person attempting to acquire the Company without Board approval. However, the Board retains the option to redeem the Rights at a price of $0.0001 per Right at any time prior to a person becoming an Acquiring Person, ensuring the plan does not interfere with mergers approved by the Board.
Risks and Contingencies:
- Redemption Restrictions: If a change in the majority of the Board occurs via proxy solicitation and a "Solicitation Participant" proposes a business combination, shareholder approval (85%) is required to redeem the Rights or amend the agreement to facilitate the transaction.
- Shareholder Rights: Until exercised, Rights holders have no voting rights or dividend rights as shareholders of the Company.
Important Facts for Investor Verification
- Verify the Record Date of December 1, 1999, to confirm eligibility for the Rights distribution.
- Review the definitive Rights Agreement (Exhibit 99.1) for specific adjustment formulas regarding stock splits or dividends.
- Note that the Rights are redeemable by the Board at a nominal price ($0.0001) unless a 10% acquisition has occurred.
- Confirm that the Rights do not confer voting or dividend rights until exercised.
- Check for any subsequent filings regarding the redemption of the Rights or changes in beneficial ownership exceeding 10%.